Clinical Testing Sample Clauses

The Clinical Testing clause defines the requirements and procedures for conducting clinical trials or studies involving a product, drug, or medical device. It typically outlines the standards for trial design, ethical considerations, regulatory compliance, and data collection, and may specify responsibilities for obtaining approvals or reporting results. By establishing clear guidelines for how clinical testing must be performed, this clause ensures that all parties adhere to legal and ethical standards, thereby protecting patient safety and supporting the validity of study outcomes.
Clinical Testing. All pre-clinical, clinical and post-clinical testing and stability testing and other actions, including but not limited to completion of the Development Program, required to obtain all requisite government approvals in the United States for the manufacture and sale of each Licensed Product shall be conducted by SANO, at its expense unless otherwise set forth herein.
Clinical Testing. The parties will use commercially reasonable efforts to perform their respective obligations set forth in the Development Program for the Clinical Testing of the Product and obtaining of Regulatory Approval for the Finished Product.
Clinical Testing. If SMI desires to conduct any clinical testing of the Monitor, where the data from such testing is expected to be presented at a public forum or be published, SMI shall advise Aspect and no such clinical testing shall occur unless Aspect shall first have approved the protocols for such clinical testing. Aspect shall not unreasonably delay or withhold its approval of such clinical testing.
Clinical Testing. All pre-clinical, clinical and post-clinical testing and stability testing including but not limited to the Clinical Product Development Program required for government health care approvals in the Territory of a Licensed Product developed by Noven shall be conducted by Noven and Rore▇, ▇▇ Rore▇'▇ ▇▇▇e expense, it being understood that Noven shall perform the clinical testing for the United States and Canada at Rore▇'▇ ▇▇▇e expense. However, before clinical testing of a product is commenced, Noven shall complete all of Rore▇'▇ ▇▇▇-clinical testing requirements set forth in Exhibit A for the Licensed Product except for the U.S. and Canada.
Clinical Testing. Upon completion of Licensee’s initial development work to incorporate the Licensed Ingredients into Products, Licensee will clinically test the initial Product in accordance with a clinical test schedule to be determined by Licensee to determine whether the Product performs in accordance with the clinical results specifications set forth in Exhibit C. Such clinical testing will be conducted in accordance with the protocols and procedures and at the locations set forth in Exhibit C, or as otherwise agreed to among Licensee, its subcontractor RF Technology Consultants Inc. (“RF Technology”), and BioKool in writing.
Clinical Testing. No royalties shall accrue for the sale of ---------------- Licensed Products in conjunction with clinical tests or trials conducted in accordance with the guidelines of the U.S. Food and Drug Administration and any other appropriate governmental agency.

Related to Clinical Testing

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.